Vildagliptin
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Vildagliptin
Description:
Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1].Product Name Alternative:
LAF237; NVP-LAF 237UNSPSC:
12352005Hazard Statement:
H302, H315, H319, H335Target:
Apoptosis; Dipeptidyl Peptidase; FerroptosisType:
Reference compoundRelated Pathways:
Apoptosis; Metabolic Enzyme/ProteaseApplications:
Metabolism-sugar/lipid metabolismField of Research:
Metabolic Disease; CancerAssay Protocol:
https://www.medchemexpress.com/Vildagliptin.htmlPurity:
99.93Solubility:
H2O : 50 mg/mL (ultrasonic)Smiles:
O[C@@]1(C2)C[C@H]3C[C@H](C[C@]2(NCC(N4[C@H](C#N)CCC4)=O)C3)C1Molecular Formula:
C17H25N3O2Molecular Weight:
303.40Precautions:
H302, H315, H319, H335References & Citations:
[1]Villhauer EB, et al. 1-[[ (3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano- (S) -pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003 Jun 19;46 (13) :2774-89.|[2]Wu YJ, et al. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in associationwith its effects suppressing endoplasmic reticulum stress in db/db mice. Metabolism. 2015 Feb;64 (2) :226-35.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Reference compound1Clinical Information:
LaunchedIsoform:
DPP-4CAS Number:
274901-16-5
